By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Viventia Biotech Inc. 

5060 Spectrum Way
Suite 405
Mississauga  Ontario  L4W 5N5  Canada
Phone: 905-361-8686 Fax: 905-361-2673


SEARCH JOBS








Company News
Viventia Biotech Inc. (VBI.TO) Begins Recruitment Of Clinical Centers As It Prepares To Initiate Phase III Clinical Trial Of Vicinium For The Treatment Of Non-Muscle-Invasive Bladder Cancer 7/2/2015 12:17:40 PM
Viventia Biotech Inc. (VBI.TO) Presents Validating Evidence For Highly Differentiated De-Immunized Payload For Oncology At 13th Empowered Antibodies Conference 6/17/2015 1:15:43 PM
Viventia Biotech Inc. (VBI.TO) to Explore Strategic Alternatives; Reports Positive Pivotal Phase III Interim Efficacy Data 1/29/2008 7:25:35 AM
Viventia Biotech Inc. (VBI.TO) Initiates Patient Treatment for Phase I Trial of VB6-845 Anti-Cancer Antibody 6/11/2007 11:03:21 AM
Viventia Biotech Inc. (VBI.TO) Reports Final Vicinium(TM) Phase I/II Bladder Cancer Data at the American Urological Association Annual Meeting 5/25/2007 10:11:13 AM
Viventia Biotech Inc. (VBI.TO) Generates Novel Human Anti-Cancer Antibody, VB1-050, and Identifies its Novel Target 4/18/2007 12:36:57 PM
Viventia Biotech Inc. (VBI.TO) Reports Synergystic Effect of its Proxinium(TM) Antibody in Combinaton with Chemotherapy and Radiation 4/18/2007 12:33:00 PM
Viventia Biotech Inc. (VBI.TO) Initiates Patient Treatment for Vicinium(TM) Phase II Bladder Cancer Trial 4/3/2007 11:35:40 AM
Viventia Biotech Inc. (VBI.TO) Provides Update On Cancer Antibody Clinical Development Programs 2/14/2007 2:30:52 PM
CODA Genomics, Inc. Announces Collaboration Expansion With Viventia Biotech Inc. (VBI.TO) 12/20/2006 4:22:05 PM
1234
//-->